# US Family Health Plan

## Prior Authorization Request Form for

# Androgel, testosterone1% and 1.62% MDP, gel and gel packets, 2% testosterone

solution MDP,1%testosterone gel in unit-dose tubes (Testim,Vogelxo, generics)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

## The completed form may be faxed to 855-273-5735

OR

## The patient may attach the completed form to the prescription and **mail** it to: Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

## QUESTIONS? Call 1-877-880-7007

Initial therapy approves for 1 year, renewal approves indefinitely. For renewal of therapy, an initial Tricare prior authorization approval is required.

Step	Please complete patient and physician information (please print):					
1	Patient Name:	Physician N	Physician Name:			
	Address:	Ado	dress:			
	· · · · · · · · · · · · · · · · · · ·					
	Sponsor ID # Date of Birth:	Pro	one #:			
Step	Please complete the clini		ux #.			
2	1. Will the requested medication be used to enhance athletic performance?		□ Yes STOP	□ No Proceed to question <b>2</b>		
			Coverage not approved			
	2. Will the requested medication be used concomitantly with other testosterone products?		□ Yes	🗆 No		
			STOP	Proceed to question 3		
			Coverage not approved			
	3. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for the requested medication.		□ Yes	🗆 No		
			Proceed to question <b>4</b>	Proceed to question <b>6</b>		
	4. Has the patient had a positive response to therapy?		□ Yes	🗆 No		
			Proceed to question 5	STOP		
				Coverage not approved		
	5. Do the benefits of conti	nued therapy outweigh the risks?	□ Yes	🗆 No		
			Sign and date on page 3	STOP		
				Coverage not approved		

6.	What is the indication or diagnosis?	□ Hypogonadism - Proceed to question <b>7</b>	
		□ Female-to-male gende therapy in a natal female female at birth) - Procee	patient (assigned
		□ Other - Proceed to question 22	
7.	Is the patient a male who is 18 years of age or older?	□ Yes	🗆 No
		Proceed to question 8	STOP
			Coverage not approved
8.	Does the patient have a confirmed diagnosis of hypogonadism as evidenced by morning total serum	□ Yes	🗆 No
	testosterone levels below 300 ng/dL taken on at least two separate occasions?	Proceed to question <b>10</b>	Proceed to question 9
9.	Is testosterone being prescribed by an endocrinologist or	□ Yes	🗆 No
	urologist who has made the diagnosis of hypogonadism based on unequivocally and consistently low serum total testosterone or free testosterone levels?	Proceed to question 10	STOP
			Coverage not approved
10.	Is the patient experiencing signs and symptoms associated with hypogonadism?	□ Yes	🗆 No
		Proceed to question <b>11</b>	STOP
			Coverage not approved
	Has the provider investigated the etiology of the low testosterone levels?	□ Yes	🗆 No
		Proceed to question <b>12</b>	STOP
			Coverage not approved
12.	Has the provider assessed the risks versus benefits of initiating testosterone therapy in this patient?	□ Yes	🗆 No
		Proceed to question 13	STOP
			Coverage not approved
	Does the provider acknowledge that testosterone therapy is clinically appropriate and needed?	□ Yes	🗆 No
		Proceed to question 23	STOP
			Coverage not approved
14.	Is the patient greater than or equal to 14 years of age?	□ Yes	🗆 No
		Proceed to question <b>15</b>	STOP
			Coverage not approved
15.	Does the patient have a diagnosis of gender dysphoria made by a TRICARE-authorized mental health provider according to the most current edition of the DSM?	□ Yes	🗆 No
		Proceed to question 16	STOP
			Coverage not approved

#### US Family Health Plan Prior Authorization Request Form for Androgel, testosterone 1% and 1.62% MDP, gel and gel packets, 2% testosterone solution MDP,1% testosterone gel in unit-dose tubes (Testim, Vogelxo, generics)

,	9	,,,	/
16. Is the requested medication being prescri endocrinologist or a physician who specie		□ Yes	□ No
treatment of transgender patients?		Proceed to question <b>17</b>	STOP
			Coverage not approved
17. Is the patient an adult, or an adolescent w mental capacity to give informed consent		□ Yes	🗆 No
irreversible treatment?		Proceed to question <b>18</b>	STOP
			Coverage not approved
18. Has the patient experienced puberty to at stage 2?	least Tanner	□ Yes	🗆 No
Stage 2 :		Proceed to question <b>19</b>	STOP
			Coverage not approved
19. Is the patient a biological female of childb	earing potential?	□ Yes	🗆 No
		Proceed to question 20	Proceed to question 21
20. Is the patient pregnant or breastfeeding?		□ Yes	□ No
		STOP	Proceed to question 21
		Coverage not approved	
1. Does the patient have a psychiatric comorbidity that would		□ Yes	🗆 No
	confound a diagnosis of gender dysphoria or interfere with treatment (for example: unresolved body dysmorphic		Proceed to question 23
disorder; schizophrenia or other psychotic disorders that have not been stabilized with treatment)?		Coverage not approved	
22. Document the requested indication and ra	ationale for use.		
		Proceed to question <b>23</b> gel (for example, generic Androgel, generic	
	Testim, etc.) - Sign and date below □ testosterone 1.62% gel (for example, generic Androgel, etc.) - Sign and date below		
	☐ testosterone 2% solution (for example, generic Axiron, etc.) - Sign and date below		
	multi-dose pump (I	ple Androderm, Fortesta ( MDP)), Natesto, brand Te: gelxo) -  Proceed to questi	stosterone 1% gel
	24. Has the patient tried and failed a 3-month trial of one of the		□ No
following medications: testosterone 1% gel (for example, generic Androgel, generic Testim, etc.), 1.62% gel (for example, generic Androgel, etc.), or 2% solution (for example, generic Axiron, etc.)?		Sign and date below	Proceed to question 25

#### US Family Health Plan Prior Authorization Request Form for Androgel, testosterone 1% and 1.62% MDP, gel and gel packets, 2% testosterone solution MDP,1% testosterone gel in unit-dose tubes (Testim, Vogelxo, generics)

Sign and date below	Proceed to question <b>26</b>
☐ Yes Sign and date below	☐ No STOP Coverage not approved

Prescriber Signature

Step

3

Date

[ 29 May 2024 ]